Figure 1
IL-13 alters mature SP-C protein level in a dose-dependent manner. Adult human ATII cells were cultured on Matrigel and rat-tail collagen coated inserts in DMEM containing 5% heat inactivated human serum with 2 d of TGFα followed by 4 d of KGF. Panel A shows a representative immunoblot from ATII cells cultured with 2 or 20 ng/ml IL-13 for the final 4 days. Lane 1: day 0 control (freshly isolated ATII cells), Lane 2: empty lane, Lane 3: 2 d 10 ng/ml TGFα + 4 d 10 ng/ml KGF, Lane 4: 2 d 10 ng/ml TGFα + 4 d 10 ng/ml KGF with 4 d 2 ng/ml IL-13, Lane 5: 2 d 10 ng/ml TGFα + 4 d 10 ng/ml KGF with 4 d 20 ng/ml IL-13. Panel B shows the reduction in mature SP-C protein levels after treatment with IL-13 (black) by immunoblotting data normalized to GAPDH (n = 3), which are analyzed by NIH Image. The comparison is to cultures without IL-13. Representative data are shown in Panel A lane 3 to 5. *: p < 0.05 v.s without IL-13.